quinuclidines has been researched along with Fibrosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Böhm, M; Distler, JHW; Flis, D; Stegemann, A; Steinbrink, K; Ziolkowski, W | 1 |
| Böhm, M; Del Rey, A; Raker, V; Stegemann, A; Steinbrink, K | 1 |
2 other study(ies) available for quinuclidines and Fibrosis
| Article | Year |
|---|---|
The α7 Nicotinic Acetylcholine Receptor: A Promising Target for the Treatment of Fibrotic Skin Disorders.
Topics: Adenoviridae; alpha7 Nicotinic Acetylcholine Receptor; Animals; Bleomycin; Bridged Bicyclo Compounds, Heterocyclic; Cells, Cultured; Collagen; Disease Models, Animal; Drug Evaluation, Preclinical; Fibroblasts; Fibrosis; Genetic Vectors; Humans; Male; Mice; Primary Cell Culture; Quinuclidines; Receptor, Transforming Growth Factor-beta Type I; Scleroderma, Systemic; Skin | 2020 |
Expression of the α7 Nicotinic Acetylcholine Receptor Is Critically Required for the Antifibrotic Effect of PHA-543613 on Skin Fibrosis.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Bleomycin; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Fibrosis; Hydroxyproline; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Quinuclidines; Skin Diseases; Transforming Growth Factor beta1 | 2022 |